[go: up one dir, main page]

MX2019003682A - Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas. - Google Patents

Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.

Info

Publication number
MX2019003682A
MX2019003682A MX2019003682A MX2019003682A MX2019003682A MX 2019003682 A MX2019003682 A MX 2019003682A MX 2019003682 A MX2019003682 A MX 2019003682A MX 2019003682 A MX2019003682 A MX 2019003682A MX 2019003682 A MX2019003682 A MX 2019003682A
Authority
MX
Mexico
Prior art keywords
rsv
nucleic acid
methods
disclosed
sequences
Prior art date
Application number
MX2019003682A
Other languages
English (en)
Inventor
B Weiner David
Choo Daniel
Mathumani Karuppiah
Obeng-Adjei Nyamekye
Scott Veronica
Original Assignee
The Trustees Of The Univ Of Pennyslvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The Univ Of Pennyslvania filed Critical The Trustees Of The Univ Of Pennyslvania
Publication of MX2019003682A publication Critical patent/MX2019003682A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen moléculas de ácido nucleico y composiciones que comprenden una o más secuencias de ácido nucleico que codifican un antígeno RSV. El ácido nucleico se describe comprendiendo las secuencias que codifican la proteína RSV F de consenso o uno de sus fragmentos inmunogénicos, secuencias que codifican a la proteína RSV G(A) o uno de sus fragmentos inmunogénicos y secuencias que codifican la proteína RSV G(B) o uno de sus fragmentos inmunogénicos. Las composiciones que comprende una, combinaciones de dos o las tres secuencias se describen. Las secuencias de codificación opcionalmente incluyen la secuencia de codificación operablemente enlazada que codifica un péptido de señal. Las moléculas de ácido nucleico y las composiciones que comprenden la quimiocina CC20 y/o una proteína RSV M2-1 de consenso o uno de sus fragmentos inmunogénicos también se describen. Los métodos inmunomoduladores e incluyendo métodos para inducir unan respuesta inmunitaria frente a RSV se describen. El método para la prevención de la infección por RSV y métodos para el tratamiento de individuos afectados con RSV se describen.
MX2019003682A 2012-04-10 2014-10-09 Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas. MX2019003682A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261622279P 2012-04-10 2012-04-10

Publications (1)

Publication Number Publication Date
MX2019003682A true MX2019003682A (es) 2019-07-18

Family

ID=49328131

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014012234A MX363667B (es) 2012-04-10 2013-04-10 Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
MX2019003682A MX2019003682A (es) 2012-04-10 2014-10-09 Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014012234A MX363667B (es) 2012-04-10 2013-04-10 Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.

Country Status (10)

Country Link
US (2) US10040828B2 (es)
EP (2) EP3511337A1 (es)
JP (3) JP2015514132A (es)
KR (1) KR20140146651A (es)
CN (1) CN104619719A (es)
AU (1) AU2013245950B2 (es)
CA (1) CA2870182A1 (es)
HK (1) HK1210479A1 (es)
MX (2) MX363667B (es)
WO (1) WO2013155205A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201608798YA (en) 2014-04-23 2016-11-29 Modernatx Inc Nucleic acid vaccines
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
CN106018780B (zh) * 2016-05-17 2017-12-26 扬州大学 一种基于f1蛋白的检测4型禽腺病毒抗体的间接免疫荧光试剂盒
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
LT3606942T (lt) 2017-04-04 2025-10-10 Savaiminės sąrankos baltymų nanostruktūros, eksponuojančios paramiksoviruso ir (arba) pneumoviruso f baltymus ir jų naudojimas
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
US11376317B2 (en) 2017-08-30 2022-07-05 University Of Maryland, College Park FcRn-targeted mucosal vaccination against RSV
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
EP3758747A1 (en) 2018-02-28 2021-01-06 University of Washington Self-asssembling nanostructure vaccines
US11591371B2 (en) 2018-04-02 2023-02-28 University Of Maryland, College Park FcRn-targeted mucosal vaccination against influenza infections
EP3852728B1 (en) 2018-09-20 2024-09-18 ModernaTX, Inc. Preparation of lipid nanoparticles and methods of administration thereof
EP4110383A4 (en) 2020-02-26 2024-02-28 University of Maryland, College Park COMPOSITIONS AND METHODS FOR MUCOSAL VACCINATION AGAINST SARS-COV-2
CN119497628A (zh) * 2023-06-20 2025-02-21 石药集团巨石生物制药有限公司 一种抵抗呼吸道合胞病毒的mRNA疫苗及其制备方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US5643579A (en) 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US4790987A (en) 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
JP3044062B2 (ja) 1989-03-08 2000-05-22 ヘルス・リサーチ・インク 組換えポックスウイルス宿主選択系
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
EP0465560B1 (en) 1989-03-31 1996-06-05 Washington University VACCINES CONTAINING AVIRULENT phoP-TYPE MICROORGANISMS
DE69016956T2 (de) 1989-12-04 1995-07-20 Akzo Nobel Nv Rekombinantes Truthahn-Herpesvirus und davon abgeleiteter Lebendimpfstoffvektor.
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
JP3285355B2 (ja) 1992-06-04 2002-05-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｉｎｖｉｖｏ遺伝子治療のための方法及び組成物
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
DE69434469T2 (de) 1993-01-26 2006-06-14 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
NZ267838A (en) 1993-06-07 1997-12-19 Genentech Inc Preparation of an hiv gp 120 subunit vaccine involving determining a neutralising epitope in the v2 and/or c4 domains
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
NL9401820A (nl) 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US5698202A (en) 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
ATE337794T1 (de) 1997-04-03 2006-09-15 Electrofect As Verfahren zum verabreichen von pharmazeutischen präparaten und nukleinsäuren an den skelettmuskel
PL337583A1 (en) 1997-06-30 2000-08-28 Rhone Poulenc Rorer Sa Improved method of transferring nucleic acid to a striated muscle and connection enabling accomplishment of this method
CA2337652C (en) 1998-07-13 2013-03-26 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6270758B1 (en) 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
US6589529B1 (en) 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
JP2002212099A (ja) * 2001-01-16 2002-07-31 Inst Of Physical & Chemical Res 腫瘍ワクチン
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
TW200501985A (en) 2002-07-25 2005-01-16 Medimmune Inc Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
EP1573004A4 (en) 2002-11-04 2006-08-09 Advisys Inc SYNTHETIC MUSCLE PROMOTERS WITH INHERENT CELLS NATURALLY OBTAINING REGULATORY SEQUENCES EXCELLENT ACTIVITIES
DK2364769T3 (en) 2003-05-30 2016-04-11 Vgxi Inc Apparatus and methods for biomaterialeproduktion
NZ570709A (en) 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
US8772256B2 (en) * 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
JP2010522540A (ja) 2007-03-21 2010-07-08 アイディー バイオメディカル コーポレイション オブ ケベック キメラ抗原
CL2007002710A1 (es) 2007-09-20 2008-01-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
EP2205751A2 (en) 2007-09-26 2010-07-14 Vanderbilt University Vaccine for rsv and mpv
US9592285B2 (en) 2007-11-12 2017-03-14 The Trustees Of The University Of Pennsylvania Vaccines against multiple subtypes of influenza virus
WO2010039224A2 (en) * 2008-09-30 2010-04-08 University Of Massachusetts Medical School Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
WO2010050939A1 (en) 2008-10-29 2010-05-06 The Trustees Of The University Of Pennsylvania Improved hcv vaccines and methods for using the same
CA2653478A1 (en) * 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
EP2453918B1 (en) * 2009-07-15 2015-12-16 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
US9095546B2 (en) * 2009-07-20 2015-08-04 National Health Research Institutes Human respiratory syncytial virus (RSV) vaccine
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
CA2804396C (en) 2010-07-06 2021-06-29 Novartis Ag Liposomes with lipids having an advantageous pka-value for rna delivery
KR20130100267A (ko) * 2010-08-09 2013-09-10 시박스, 인크. 질환을 예방하기 위한 방법 및 조성물
CN103239734B (zh) 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 用于预防和/或治疗呼吸道合胞病毒感染的疫苗
GB2504774A (en) 2012-08-10 2014-02-12 Munster Simms Eng Ltd Diaphragm pump with integral motor housing and rear pump housing
TWI548337B (zh) 2015-10-16 2016-09-01 技嘉科技股份有限公司 散熱模組、顯示卡組件及電子裝置

Also Published As

Publication number Publication date
EP2836505A1 (en) 2015-02-18
JP2019112414A (ja) 2019-07-11
JP2015514132A (ja) 2015-05-18
WO2013155205A9 (en) 2013-12-05
US11021520B2 (en) 2021-06-01
AU2013245950B2 (en) 2016-04-21
EP2836505B1 (en) 2019-01-23
EP2836505A4 (en) 2015-12-02
CN104619719A (zh) 2015-05-13
EP3511337A1 (en) 2019-07-17
HK1210479A1 (en) 2016-04-22
US20180346522A1 (en) 2018-12-06
KR20140146651A (ko) 2014-12-26
WO2013155205A1 (en) 2013-10-17
JP2018065824A (ja) 2018-04-26
CA2870182A1 (en) 2013-10-17
AU2013245950A1 (en) 2014-10-30
US10040828B2 (en) 2018-08-07
MX2014012234A (es) 2014-12-05
MX363667B (es) 2019-03-29
US20150079121A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
MX2019003682A (es) Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
CO2018005229A2 (es) Vacuna de virus sincitial respiratorio
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
PH12018500916A1 (en) Antibody neutralizing human respiratory syncytial virus
MX2020001385A (es) Composiciones que comprenden construcciones geneticas y vacunas de il-12 mejoradas, agentes inmunoterapeuticos y metodos para su uso.
MX384992B (es) Combinaciones inmunógenas.
CY1117673T1 (el) Ανασυνδυασμενα αντιγονα rsv
EA201070794A1 (ru) Рекомбинантные антигены rsv
EP4043031A3 (en) Zika viral antigen constructs
WO2012106377A3 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
AU2014232363A8 (en) Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
WO2013120628A8 (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
IN2014DN09351A (es)
HK1254344A1 (zh) 抗原匹配的流感疫苗
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
EA202090759A2 (ru) Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
MX2018003352A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
SA522441314B1 (ar) لقاحات لوُرام حليمي تنفسي متكرر وطرق استخدامها
WO2016116905A9 (en) Cmv antigens and uses thereof
DK3016673T3 (da) Pattedyrsmælkeosteopontin til forbedring af immunreaktion
MX2023003934A (es) Antigenos de consenso de filovirus, construcciones de acido nucleico y vacunas realizadas a partir de estos, y metodos para utilizarlos.
WO2014140166A3 (en) Vaccine
WO2009074861A3 (en) Improved vaccine